Comparing survival outcomes for advanced cancer patients who access comprehensive genomic sequencing using a registry-based synthetic control arm.

Abstract

e18851 Background: Studies evaluating the clinical benefit from Comprehensive Genomic Sequencing (CGS) in cancer patients (pts) have been limited by heterogeneous populations in cancer types and treatment history, outcomes analysis focused on pts who received treatment, and single arm designs. This study evaluated the clinical utility of CGS in a unique real-world advanced cancer patient cohort by comparing a series of pts who received CGS to inform investigational treatment compared to those who did not. Methods: Two cohorts of advanced and refractory pts with diverse cancer types seen for early phase trial consideration were identified from the Peter MacCallum Cancer Centre (PMCC) phase 1..